The Psoriasis Drugs Market is expected to grow at a stupendous rate in the next 10 years. The healthcare industry is being driven by innovation. The very idea of “Customer is the King” is being implemented. As such, healthcare IT solutions come across as a meticulous and complex system that constitutes interconnected and large-scale systems wherein micros are being worked upon. These would be the facets of the healthcare vertical going forward.
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 – 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to expand at a CAGR of nearly 6.5% over the next ten years.
An array of agents exist for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis typically receive topical treatments that modulate gene transcription, promote keratinocyte differentiation, and inhibit cell proliferation.
Planning Forward? Access Sample Of Psoriasis Drugs Market Report! https://www.persistencemarketresearch.com/samples/25102
A number of innovative and advanced therapies for the treatment and management of psoriasis are under development, many of which have novel targets and mechanisms of action. Psoriasis is linked with a number of medical conditions inclusive of psoriatic arthritis, depression, and cardio metabolic syndrome. The most commonly occurring form of psoriasis is chronic plaque.
Common treatment methods of psoriasis include topical administration of vitamin D analogues, glucocorticoids, and phototherapy. Moderate to severe psoriasis often calls for systemic treatment.
Prevalence of psoriasis has displayed a growing trend over the past decade. Rising awareness initiatives regarding psoriasis disease and its management & treatment options, increasing reimbursement support, and growing research & development with the adoption of biologics and biosimilars are some of the factors responsible for impacting the psoriasis drugs market and aiding sales growth.
- Janssen Biotech, Inc.
- Novartis International Ltd.
- Amgen Inc
- Pfizer Inc.
- Takeda Pharmaceutical Company Ltd.
- Merck & Co, Inc.
- Abb Vie Inc.
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Sun Pharmaceutical Industries Ltd
How About Revitalizing The Strategy-Oriented Funnel To Stay Ahead In The Psoriasis Drugs Market? https://www.persistencemarketresearch.com/methodology/25102
Key Takeaways from Market Study
- Topical products are expected to continue holding over one-third market value share through 2031, primarily because of clinically approved topical ointments, foams, and creams available for the management of inflammation and rash due to psoriasis.
- Efficiency of corticosteroids for skin irritability and inflammation makes corticosteroid the leading segment with over 34% of revenue share in 2021.
- Easy availability of psoriasis drugs in hospital pharmacies and large distribution networks of hospital chains make it the largest segment, with more than 39% market share.
- Plaque psoriasis is the most commonly occurring autoimmune disease, accounting for a revenue share of around 85% in 2021.
- Presence of a large number of manufacturers, rising public awareness, and easy availability of psoriasis drugs and treatment options make North America the leading regional market with over 27% market share in 2021.
“Growing adoption of combination therapy and favourable reimbursement support for psoriasis to drive market growth,” says an analyst of Persistence Market Research.
Planning To Introduce An Offbeat Product/Technology In The Psoriasis Drugs Market? Go To “Purchase Now” To Have Our Psoriasis Drugs Market Report! https://www.persistencemarketresearch.com/checkout/25102
Companies such as Amgen and Sun Pharma have been strongly working toward the development of an extensive clinical pipeline and manufacturing of new product lines for the treatment of psoriasis.
- In December 2021, Amgen announced positive top-line results from the Otezla® (apremilast) Phase 3 DISCREET study in moderate to severe genital psoriasis.
- In September 2020, Sun Pharma announced the launch of ILUMYA® (tildrakizumab) for the treatment of plaque psoriasis, in Japan.
Similarly, other psoriasis drug manufacturers are also trying to maintain and strengthen their portfolios through collaborations with local players or distribution partners. All such recent developments related to companies manufacturing psoriasis drugs have been tracked by the team at Persistence Market Research, which are available in the full report.
Key companies operating in the psoriasis drugs market include Janssen Biotech Inc, Novartis International Ltd., Amgen Inc, Pfizer Inc., Takeda Pharmaceutical Company Ltd. Merck & Co, Inc., Abb Vie Inc., Eli Lilly and Company, Boehringer Ingelheim GmbH, and Sun Pharmaceutical Industries Ltd.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the psoriasis drugs market in its latest study, presenting a historical demand assessment of 2016 – 2021 and projections for 2022 – 2031.
The research study is based on the product (topical, oral, and injectable), drug class (interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitor), distribution channel (hospital pharmacies, retail pharmacies, and e-Commerce), and indication (guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, and plaque psoriasis), across seven key regions of the world.
Access Related Reports-
Confocal Microscope Market–
The global confocal microscope market is projected to grow at a CAGR of 3.3% throughout the forecast period (2018–2028).
The immuno-oncology therapy has shown excellent results in various clinical trials and in patients being treated with immune-oncology therapy. Immuno-oncology therapies can leverage patients’ immune systems and re-program the same to attack cancer cells, providing a safe and effective alternative.
Enteral Nutrition Market-
Enteral nutrition administration is the administration of food and drug via the human gastrointestinal tract. This is different from the parenteral nutrition or drug administration which occurs from routes such as intravenous.
About Us: Persistence Market Research
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – firstname.lastname@example.org